News
What’s Next for the ACA?
Advocacy & Legislation, Industry News & Research
The recent news about the passing of United State Supreme Court Justice Ruth Bader Ginsburg and nomination of Judge Amy Coney Barrett…
CSL Behring States Stimate Will Not Be Resupplied until 2022
Industry News & Research
NHF and HFA have been provided the following statement from CSL Behring. The statement says, in part: “Ferring Pharmaceuticals Inc. initiated a voluntary,…
Milwaukee County COVID-19 Update
COVID-19, Industry News & Research
The Milwaukee Unified Emergency Operations Center continues to put out up-to-date information for the citizens of Milwaukee County. This information is also…
NHF Wants Your Input as They Chart a Course for the Future. Take Their Survey Today!
Industry News & Research
The National Hemophilia Foundation (NHF) is working with the bleeding disorders community to envision our future for the next decade, and they…
NHF Friday Webinar – Gene Therapy: What’s New and What’s Next? October 2, 3 pm.
Industry News & Research
Gene therapy for hemophilia remains a very active area of research, although it may take longer than expected. To discuss this, join…
Emergency Preparedness
Industry News & Research
The NHF is saddened by the loss of life and destruction of communities due to catastrophic fires in the west and a…
Unanswered Questions Remain in Gene Therapy
Gene Therapy, Industry News & Research, Living with a Bleeding Disorder
A recent commentary published in the journal Haemophilia, posits that while clinical trials for hemophilia gene therapy approach conclusion, there remain significant unanswered…
Sanofi Publishes Updates to BIVV001 Trial
Industry News & Research
Sanofi recently announced results from their phase 1/2a EXTEN-A trial for their investigational therapy BIVV001, which were published in the New England Journal…
Hemophilia B Therapy to be Discontinued
Industry News & Research
CSL Behring recently announced that they are discontinuing Mononine®, the company’s human plasma-derived factor therapy indicated for the prevention and control of…
NHF’s Board of Directors Meeting
Industry News & Research
The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT. The Board…
Genentech Provides Updates on Hemlibra Product Particles
Industry News & Research
In the fall of last year Genentech reported that during a routine examination of batches of Hemlibra®, they found translucent particles composed…
NHF, HFA and Hemophilia Alliance Continue Push for Information on Stimate Recall
Industry News & Research
The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) continue to follow up on issues arising from the recent recall of Stimate (desmopressin)…
New MASAC Recommendations Focus on Offsite Hemostasis Screening and Treatment
Industry News & Research
The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) issued two new documents, which were adopted by NHF’s Board of…
Mental Health During Coronavirus
COVID-19, Industry News & Research
by: Debbie de la Riva The collective pursuit to control the spread of coronavirus has resulted in an enormous challenge for the…
NHF’s 2020 Bleeding Disorders Conference Available On Demand Through September 30!
Industry News & Research
NHF’s Bleeding Disorders Conference was fully virtual this year and included more than 50 sessions. Those sessions are all available on-demand until…
BioMarin’s New Clinical Study to Focus on Antibody Development to AAVs
Industry News & Research
Last month, BioMarin learned that approval for their investigational hemophilia A gene therapy was not forthcoming but would in fact be delayed…
Mylan Initiates Voluntary Nationwide Recall of Four Lots of Tranexamic Acid Injection, USP Due to Carton Label Mix-Up
Industry News & Research
On September 1, 2020, NHF and HFA learned that Mylan N.V. is conducting a voluntary nationwide recall of four lots of Tranexamic Acid Injection,…
NHF Receives Five-Year CDC Grant for Education Programs
Industry News & Research
The National Hemophilia Foundation (NHF) has received a five-year cooperative agreement from the Centers from Disease Control and Prevention (CDC). The collaboration,…
BioMarin Hemophilia A Clinical Development Program: An Update for the Hemophilia Community
Industry News & Research
BioMarin is committed to updating the community regarding our ongoing gene therapy clinical trial program in hemophilia A. BioMarin’s investigational gene therapy…
FDA Recommends Additional Data for BioMarin’s Investigational Gene Therapy
Gene Therapy, Industry News & Research, Living with a Bleeding Disorder
Biomarin announced that they received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 18th for their…
Novo Nordisk Announces Near Resumption of Concizumab Trials
Industry News & Research
Novo Nordisk has announced that clinical trials for their investigational subcutaneous therapy concizumab will resume after an approximate five month pause, initiated…
Medical Advisory #427: Stimate Recall Update
Industry News & Research
August 13, 2020 CSL Behring and Ferring Pharmaceuticals have announced additional information about a recent recall of lots of Stimate® that was…
A New Study of Hemophilia Occurrence Finds Many More Cases in the United States
Industry News & Research
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly due to a lack or decrease in a…
MASAC Encourages People with Bleeding Disorders to be Included in COVID-19 Vaccine Trials
COVID-19, Industry News & Research
Individuals with inherited and acquired bleeding disorders, including hemophilia have substantial deficits in coagulation, for which they receive a variety of protein…